Peerview Family Medicine & General Practice Cme/cne/cpe Audio Podcast

Go online to PeerView.com/TFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in the management of venous thromboembolism (VTE) discuss the importance of a timely diagnosis, appropriate treatment selection, and extended anticoagulation therapy for secondary prevention. Upon completion of this activity, participants should be better able to: Apply appropriate evidence-based clinical decision tools in an interprofessional manner to identify patients in primary care at risk for VTE, Compare the efficacy and safety profile and dosing regimens of available treatment options for VTE, Implement the most up-to-date evidence-based guidelines in the management of VTE to determine an individually appropriate treatment strategy for each patient, Explain the indications and rationale for standard vs extended treatment for the secondary prevention of VTE, Educate patients on the heightened risk of VTE recurrence, and the importance of trea

Go online to PeerView.com/FFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the life-changing impact of gene replacement therapy in spinal muscular atrophy. Upon completion of this CE activity, participants will be able to: Recognize the underlying genetics and pathophysiology of spinal muscular atrophy, Identify appropriate patients with SMA for treatment with gene replacement therapy, Counsel patients, families, and caregivers about gene replacement therapy for SMA, including eligibility, potential benefits and risks, and anticipatory guidance regarding prognosis, the need for ongoing care, and long-term safety monitoring, Employ post-treatment multidisciplinary management plans for patients who have been treated for SMA with gene replacement therapy.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/GAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated, visually-enhanced activity, an expert in hematology-oncology discusses current standards for diagnosing and treating idiopathic thrombocytopenic purpura—and provides an update on the challenges associated with modern care and the promise of novel therapeutic options for disease management. Upon completion of this CE activity, participants will be able to: Discuss current challenges, unmet needs, and newer developments in ITP including the importance of differential diagnosis, testing, and guideline recommendations in treatment decision-making, Analyze safety, efficacy, evidence, and mechanism of action of BTKis and other emerging agents to improve quality of life and invoke long-term, off-treatment remissions, Develop personalized treatment plans for front-line and second-line therapies based on patient- and disease-specific factors to improve patient outcomes

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation

Go online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, a panel of leading bladder cancer experts will pair important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide thera

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment

Go online to PeerView.com/TCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in MS discuss the rationale, evidence, and practical potential for BTK inhibitors in patient-centered MS care. Upon completion of this CE activity, participants will be able to: Describe the rationale for inhibiting Bruton’s tyrosine kinase (BTK) to treat multiple sclerosis (MS), Evaluate current evidence related to the efficacy and safety of BTK inhibitors in the treatment of MS, Identify patients who could benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

Go online to PeerView.com/GZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Clinicians who treat patients with prostate cancer have new opportunities to improve outcomes across a variety of settings, but the rapid expansion of treatment options has also presented dilemmas for those trying to choose the right treatment for the right patient. For instance, next-generation anti-androgen agents have proven efficacious in early stages of prostate cancer, while approvals of poly (ADP-ribose) polymerase (PARP) inhibitors are available in later-line metastatic castration-resistant prostate cancer (mCRPC). Combination approaches, under investigation across various stages of prostate cancer, further highlight the expansive opportunities for treatment personalization across the disease continuum. Given this new wealth of options, how do clinicians determine the best treatment course for each patient? Join PeerView and the Prostate Conditions Education Council for

Go online to PeerView.com/SWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses new and emerging therapies addressing unmet patient needs in the management of schizophrenia and bipolar disorder. Upon completion of this activity, participants should be better able to: Describe the barriers and challenges associated with the treatment of patients with schizophrenia and bipolar disorder, Assess the mechanisms of action, efficacy, safety, and tolerability profiles of available and emerging therapies for the management of schizophrenia and bipolar disorder, Incorporate shared decision-making between the interprofessional healthcare team and patients in the individualized management of schizophrenia and bipolar disorder to maximize treatment and mitigate adverse events and disease relapse.

Go online to PeerView.com/FCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology provides practical guidance across the spectrum of care from screening and diagnosis to management of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Discuss the epidemiology and disease burden of NAFLD/NASH, Describe the relationship between NAFLD/NASH and cardiovascular disease, Assess current and emerging treatments for NASH in the context of mechanism of action (eg, ability to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression) and current clinical evidence (eg, impact on fibrosis and cardiovascular risk; safety)

Go online to PeerView.com/KZA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A multidisciplinary panel of experts discuss the expanding role of neuroimaging in the diagnosis and management of Alzheimer’s disease. Upon completion of this CE activity, participants will be able to: Assess the relative utility of the structural, functional, and molecular neuroimaging techniques used in AD diagnosis and management, Implement an evidence-based, guideline-directed approach to using neuroimaging to assess amyloid burden when confirming a diagnosis of AD or determining patient eligibility for use of amyloid-lowering therapy, Apply validated neuroimaging techniques and biomarkers to monitor for treatment response, disease progression, and ARIA or other adverse events in patients being treated for AD, Employ a patient-centered, multidisciplinary approach to patient care in AD

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/JUV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses new and emerging therapies addressing unmet patient needs in the management of schizophrenia and bipolar disorder. Upon completion of this activity, participants should be better able to: Describe the barriers and challenges associated with the treatment of patients with schizophrenia and bipolar disorder, Assess the mechanisms of action, efficacy, safety, and tolerability profiles of available and emerging therapies for the management of schizophrenia and bipolar disorder, Incorporate shared decision-making between the interprofessional healthcare team and patients in the individualized management of schizophrenia and bipolar disorder to maximize treatment and mitigate adverse events and disease relapse.

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Go online to PeerView.com/YQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hematology-oncology provides an overview of paroxysmal nocturnal hemoglobinuria (PNH) and discusses current and emerging treatment options for managing PNH. Upon completion of this CE activity, participants will be able to: Discuss the complement pathway and its mechanistic relationship to paroxysmal nocturnal hemoglobinuria (PNH), Summarize efficacy and safety data surrounding complement pathway inhibitors, including factor B inhibitors, to treat PNH, Manage the unique adverse events associated with complement pathway inhibitors for PNH.

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Go online to PeerView.com/YVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hyperkalemia is a potentially life-threatening condition caused by the inability of the kidneys to excrete potassium sufficiently. Excessive potassium levels can lead to cardiac arrhythmias and sudden cardiac death. Hyperkalemia is often encountered in hospitalized patients and frequently recurs after discharge. The problem is further complicated by the fact that guideline-directed medical therapies frequently used to reduce cardiorenal risks in patients with heart failure (HF) or chronic kidney disease (CKD) can increase the risk of hyperkalemia. Newer potassium binders may allow these patients to better tolerate guideline-directed therapies, as well as reduce the risk of hyperkalemia recurrence. Interprofessional models of care, such as those involving the pharmacist in transition-of-care interventions, have also been shown to improve patient outcomes. In this activity, based

Go online to PeerView.com/VUG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric growth hormone deficiency (pGHD) discusses the latest advances in treatment and patient-centered approaches to care. Upon completion of this activity, participants should be better able to: Identify appropriate pediatric candidates for growth hormone (GH) therapy based on approved indications, current recommendations, and relevant diagnostic test results, Evaluate evidence regarding the clinical characteristics (eg, efficacy, safety and tolerability, ease of administration, dosing frequency) of available and emerging GH therapies, Individualize pediatric GH therapy to include efforts that address patient needs and preferences, such as personalized dosing, therapeutic monitoring, and assistance with care transitions.

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with thera